Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The hypothesis is that a subset of patients with chronic fatigue syndrome/ myalgic
encephalomyelitis (CFS/ME), including also patients with no clinical response after B-cell
depletion therapy using the anti-CD20 antibody Rituximab, may benefit from tumor necrosis
factor-alpha inhibition using Etanercept as weekly subcutaneous injections.